Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-213: Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
jRCT2080225276Phase 2Completed
- Sponsor
- Incyte
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parsaclisib in follicular lymphoma (FL), sponsored by Incyte. Primary endpoint: Objective response rate (ORR). Started Jul 2020; status: completed.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2080225276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225276.